Register for our free email digests:
Latest From Vascular Biogenics Ltd.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2016.
Israeli biotech will commence its Phase III recurrent glioblastoma trial in mid-2015, believes combination therapy with its VB-111 and Avastin can improve overall survival. As it starts its first Phase III trial, VBL also halted work on its lead anti-inflammatory product.
IPO TABLES: Third quarter update, plus three companies price offerings, one sets terms, one files and two postpone
There were 26 initial public offerings by health care companies in the US during the third quarter of 2014, including 19 biotechnology firms, but returns from those offerings were mixed, according to the IPO-tracking firm Renaissance Capital.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.